Hwail Pharm Co Ltd

Hwail Pharm Co Ltd maintains a strong liquidity position, with a current ratio of 21.74 and cash and equivalents amounting to KRW 61,468,769,170, which significantly exceeds its total liabilities of KRW 6,288,608,410. The company's price-to-book ratio of 3.54 suggests that the market is valuing its equity at a premium relative to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible assets are being capitalized. The company's debt-to-equity ratio is effectively zero, reflecting a conservative capital structure with no long-term debt obligations.

Profitability metrics for Hwail Pharm Co Ltd are weak, with a net loss of KRW 233,014,530 and an operating loss of KRW 2,226,795,030 in the latest reporting period. The return on equity (ROE) and return on assets (ROA) are both negative at -0.0011, indicating that the company is not generating returns for its shareholders or asset base. These figures fall below the typical performance benchmarks for the pharmaceutical industry, which generally expects positive ROE and ROA figures, especially for firms with strong R&D pipelines and market presence.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regulatory changes or shifts in demand for its core products. No specific geographic regions or markets are disclosed as contributing to the company's revenue, which limits the ability to assess regional exposure.

Hwail Pharm Co Ltd's growth trajectory appears to be constrained in the near term, with no disclosed revenue growth in the latest period and a negative operating cash flow of KRW 2,829,073,940. The company's capital expenditures of KRW 3,994,527,410 suggest ongoing investment in infrastructure or production capabilities, but the negative free cash flow indicates that these investments are not yet generating positive returns. The absence of a clear growth strategy or R&D pipeline disclosure in the financial data raises concerns about the company's long-term competitiveness.

The company's risk profile is currently low, with no immediate liquidity or dilution flags detected in its filings. The absence of long-term debt and the high level of cash reserves reduce the likelihood of near-term financial distress. However, the company's negative net income and operating income suggest that it may need to raise additional capital in the future to fund operations or expansion, which could lead to dilution for existing shareholders. No recent events, such as regulatory actions or significant business developments, have been disclosed in the available financial data.